You are here

  • Home
  • Archive
  • Volume 6, Issue 1
  • Purinergic targeting enhances immunotherapy of CD73+ solid tumors with piggyBac-engineered chimeric antigen receptor natural killer cells

Article info

Article menu

Download PDFPDF

Research Article
Purinergic targeting enhances immunotherapy of CD73+ solid tumors with piggyBac-engineered chimeric antigen receptor natural killer cells

Authors

  • Jiao Wang Department of Industrial and Physical PharmacyPurdue University 575 Stadium Mall Drive, Robert E. Heine Pharmacy Building West Lafayette IN USA PubMed articlesGoogle scholar articles
  • Kyle B. Lupo Department of Industrial and Physical PharmacyPurdue University 575 Stadium Mall Drive, Robert E. Heine Pharmacy Building West Lafayette IN USA PubMed articlesGoogle scholar articles
  • Andrea M. Chambers Department of Industrial and Physical PharmacyPurdue University 575 Stadium Mall Drive, Robert E. Heine Pharmacy Building West Lafayette IN USA PubMed articlesGoogle scholar articles
  • Sandro Matosevic Department of Industrial and Physical PharmacyPurdue University 575 Stadium Mall Drive, Robert E. Heine Pharmacy Building West Lafayette IN USA Center for Cancer ResearchPurdue University 47907 West Lafayette IN USA PubMed articlesGoogle scholar articles

Citation

Wang J, Lupo KB, Chambers AM, et al
Purinergic targeting enhances immunotherapy of CD73+ solid tumors with piggyBac-engineered chimeric antigen receptor natural killer cells
Journal for ImmunoTherapy of Cancer 2018;6:136. doi: 10.1186/s40425-018-0441-8
Online issue publication 
February 10, 2021

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.